Adjuvant topical chemotherapy versus immunotherapy in primary superficial transitional cell carcinoma of the bladder

Br J Urol. 1991 Jan;67(1):70-3. doi: 10.1111/j.1464-410x.1991.tb15072.x.


In a prospective randomised controlled study, the efficacy of ethoglucid was compared with that of keyhole-limpet haemocyanin (KLH) in preventing recurrent tumours following transurethral resection of primary superficial transitional cell carcinoma of the bladder. Patients treated with ethoglucid (n = 39) received 0.565 g (1% solution) ethoglucid weekly for 6 weeks and then monthly for 1 year. Patients treated with KLH (n = 38) were immunised subcutaneously with 1 mg KLH; bladder instillations of 30 mg were then given weekly for 6 weeks and thereafter monthly for 1 year. The recurrence rates, disease-free intervals and tumour progression rates were evaluated. The end-point of the study was either progression in stage or grade or more than 1 recurrence during the observation period. The minimum length of follow-up was 1 year. The recurrence rates, mean disease-free intervals and progression rates in the 2 groups showed no statistically significant differences.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Administration, Intravesical
  • Adult
  • Aged
  • Aged, 80 and over
  • Carcinoma, Transitional Cell / surgery
  • Carcinoma, Transitional Cell / therapy*
  • Combined Modality Therapy
  • Ethoglucid / therapeutic use*
  • Female
  • Hemocyanins / therapeutic use*
  • Humans
  • Immunotherapy*
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local / prevention & control
  • Prospective Studies
  • Risk Factors
  • Urinary Bladder Neoplasms / surgery
  • Urinary Bladder Neoplasms / therapy*


  • Ethoglucid
  • Hemocyanins
  • keyhole-limpet hemocyanin